Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesNuvation Bio Inc

Nuvation Bio Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
4.28 USD 0.12 ( 2.88%)
Last update at 2026-11-09T18:07:00Z
VOLUME
1664221
Market Cap
2036.51M

Momentum Score

…

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
4.08
Low
4.33
High
52 Week Price Range
2.99
Low
9.75
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Nuvation Bio Inc is a clinical-stage biopharmaceutical company developing targeted therapies for cancer. Long-term growth may be driven by progress in its clinical pipeline, regulatory approvals and strategic partnerships, and investors may find upside if programs achieve positive trial readouts addressing unmet oncology needs.

Key risks include clinical trial failures and regulatory setbacks, substantial financing requirements that could dilute shareholders, and intense competition in oncology drug development.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
4.16
Dividend Yield
-
Revenue TTM
169.90M
Revenue Per Share
0.50
Gross Profit TTM
149.81M
Debt / Equity
0.03
ROE
-47.81%
Net Debt
-153.94M
ROCE
-37.25%
Diluted EPS TTM
-0.44

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -204.63M -567.94M -75.80M -104.20M -86.85M
Net income -204.63M -567.94M -75.80M -88.66M -79.73M
Selling general administrative 151.56M 66.73M 28.53M 31.92M 24.28M
Selling and marketing expenses - 2.50M 1.70M - 0.64M
Gross profit 54.46M 0.80M -0.22M - -
Reconciled depreciation 1.74M 0.68M 0.22M 0.20M 0.18M
Ebit -190.94M -567.60M -75.80M -119.73M -93.32M
Ebitda -189.21M -566.91M -75.58M -128.69M -97.28M
Depreciation and amortization 1.74M 0.68M 0.22M -8.96M -3.97M
Non operating income net other - - - 15.54M 6.63M
Operating income -213.06M -592.63M -99.82M -119.73M -93.32M
Other operating expenses 275.97M 600.50M 99.82M 119.73M 93.32M
Interest expense 13.68M 0.34M 0.00M -9.16M 0.64M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 21.43M 27.06M 24.61M 7.45M 2.96M
Net interest income 7.75M 26.72M 24.61M 7.45M 2.96M
Income tax expense - - - -15.54M -7.11M
Total revenue 62.90M 7.87M 0.00M 0.00M 0.00M
Total operating expenses 267.52M 593.42M 99.82M 119.73M 93.32M
Cost of revenue 8.44M 7.08M 0.22M - -
Total other income expense net 8.44M 24.69M 24.02M 15.54M 6.47M
Net income from continuing ops -204.63M -567.94M -75.80M -104.20M -86.85M
Net income applicable to common shares - - - -104.20M -86.85M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 594.82M 540.63M 621.48M 672.14M 776.15M
Intangible assets 11.21M 4.62M - - -
Other current assets 11.54M 7.27M 1.52M 3.82M 3.64M
Total liab 289.11M 76.84M 16.36M 17.07M 30.15M
Total stockholder equity 305.72M 463.79M 605.12M 655.08M 746.00M
Other current liab 65.15M 32.15M 9.65M 9.82M 12.14M
Common stock 1421.27M 1373.96M 947.75M 927.60M 909.99M
Capital stock 1421.27M 1373.96M 947.75M 927.60M 909.99M
Retained earnings -1115.37M -910.74M -342.80M -267.00M -162.80M
Other liab - - - 0.85M 11.04M
Other assets - - 0.00M 0.14M 0.42M
Cash 164.09M 35.72M 42.65M 101.10M 132.42M
Total current liabilities 82.23M 58.24M 13.97M 13.16M 16.93M
Current deferred revenue - 11.12M - - -
Net debt -153.94M -26.81M -38.64M -96.84M -129.37M
Short term debt 7.60M 7.95M 1.97M 1.21M 0.86M
Short long term debt 5.72M 6.28M - - -
Short long term debt total 10.15M 8.91M 4.01M 4.26M 3.06M
Other stockholder equity - - - -5.53M -745.25M
Property plant equipment - - - 0.89M 3.66M
Total current assets 571.52M 526.25M 616.43M 667.32M 772.07M
Net tangible assets - - - 655.08M 746.00M
Short term investments 365.12M 466.97M 568.56M 559.91M 632.97M
Net receivables 19.36M 16.29M 3.70M 2.48M 3.04M
Long term debt 47.21M - - - -
Inventory 11.41M 0.00M - - 643.08M
Accounts payable 9.48M 6.35M 2.21M 2.14M 3.92M
Accumulated other comprehensive income -0.19M 0.57M 0.18M -5.53M -1.19M
Common stock total equity - - - 927.60M 909.99M
Retained earnings total equity - - - -267.00M -162.80M
Non currrent assets other 7.61M 6.76M 0.73M 559.49M 0.42M
Non current assets total 23.30M 14.37M 5.05M 4.82M 4.08M
Capital lease obligations 4.42M 2.63M 4.01M 4.26M 3.06M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 107.87M 122.70M 8.92M 63.81M -454.39M
Change to liabilities - - - -4.11M 1.86M
Total cashflows from investing activities 99.52M 122.70M 8.92M 63.46M -454.67M
Net borrowings 48.20M -4.55M 0.00M - -
Total cash from financing activities 202.53M 0.33M 0.63M 1.33M 625.53M
Change to operating activities - - - -1.66M 2.93M
Net income -204.63M -567.94M -75.80M -104.20M -86.85M
Change in cash 128.36M -6.93M -58.45M -31.32M 102.67M
Begin period cash flow 35.72M 42.65M 101.10M 132.42M 29.75M
End period cash flow 164.09M 35.72M 42.65M 101.10M 132.42M
Total cash from operating activities -173.43M -130.41M -68.00M -96.11M -68.19M
Issuance of capital stock - - - - 0.00M
Depreciation 1.74M 0.68M 0.22M 0.20M 0.18M
Other cashflows from investing activities 99.52M 110.44M 0.01M 0.01M -
Change to inventory -11.41M 0.00M - - -
Change to account receivables -3.07M -12.59M -1.22M - -
Sale purchase of stock - - - 0.94M 0.76M
Other cashflows from financing activities 202.53M 4.88M 0.63M 1.33M 625.53M
Change to netincome - - - 7.38M 13.68M
Capital expenditures 0.35M 0.16M 0.07M 0.37M 0.28M
Change receivables - - - 0.55M -1.95M
Cash flows other operating - - - 0.39M -10.77M
Cash and cash equivalents changes - - - -31.32M 102.67M
Change in working capital -11.98M -12.51M 0.54M -3.45M 4.79M
Stock based compensation 35.89M 32.27M 19.51M 16.29M 9.27M
Other non cash items 5.55M 417.07M -12.47M -4.95M 3.97M
Free cash flow -173.78M -130.57M -68.07M -96.48M -68.47M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NUVB
Nuvation Bio Inc		 0.12
2.88%		 4.28 - - 11.99 8.22 9.87 2.23
NVO
Novo Nordisk A/S		 1.03
2.56%		 41.34 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.49
0.27%		 548.58 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 18.16
2.01%		 922.51 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Nuvation Bio Inc

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.

1500 Broadway, New York, NY, United States, 10036

332 208 6102

https://www.nuvationbio.com

305

Name Title Year Born
Dr. David T. Hung M.D. Founder, Pres, CEO & Director 1958
Ms. Jennifer A. Fox CFO & Sec. 1972
Dr. David C. Hanley Ph.D. Chief Technical Operations Officer 1970
Dr. Gary Hattersley Ph.D. Chief Scientific Officer 1967
Ms. Stacy Markel Chief People Officer 1965
Ms. Kerry A. Wentworth Chief Regulatory Officer 1973
Dr. David Liu M.D., Ph.D. Chief Medical Officer NA
Dr. David T. Hung M.D. Founder, President, CEO & Chairman 1958
Mr. Philippe Pierre Sauvage CFO & Principal Financial Officer 1978
Mr. Moses Makunje CPA VP of Finance and Principal Accounting & Financial Officer 1979

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.94
+37.96%
MOON
CAD 4.90
+11.11%
UCU
CAD 2.37
+10.75%
ANRG
CAD 1.90
+10.47%
EPRX
CAD 10.71
+10.30%
DIV
CAD 3.77
-7.37%
CSU
CAD 3281.97
-6.93%
LMN
CAD 26.62
-5.23%
TOI
CAD 99.75
-4.80%
GRZ
CAD 5.05
-4.72%

Equity Sectors*

  • Basic Materials

    +4.21%

  • Communication Services

    -0.63%

  • Consumer Cyclical

    +1.12%

  • Consumer Defensive

    +0.09%

  • Energy

    +1.91%

  • Financial Services

    +1.63%

  • Healthcare

    +1.49%

  • Industrials

    +3.56%

  • Real Estate

    +0.66%

  • Technology

    +1.84%

  • Utilities

    +1.24%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…